Kaposi's sarcoma after T‐cell costimulation blockade with abatacept in rheumatoid arthritis: a case report | Zendy

Olivo D. | Zendy; Grembiale R. D. | Zendy; Tallarigo F. | Zendy; Russo E. | Zendy; De Sarro G. | Zendy; Ursini F. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Kaposi's sarcoma after T‐cell costimulation blockade with abatacept in rheumatoid arthritis: a case report

Author(s) -

Olivo D.,

Grembiale R. D.,

Tallarigo F.,

Russo E.,

De Sarro G.,

Ursini F.

Publication year - 2017

Publication title -

journal of clinical pharmacy and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.622

H-Index - 73

eISSN - 1365-2710

pISSN - 0269-4727

DOI - 10.1111/jcpt.12510

Subject(s) - abatacept , rheumatoid arthritis , medicine , blockade , arthritis , sarcoma , dermatology , immunology , pathology , receptor , lymphoma , rituximab

Summary What is known and objective Kaposi's sarcoma ( KS ) is a malignant neoplasm caused by HHV ‐8, a pathogen that leads to endothelial cell transformation when host defences are weakened. Case description Here we report the first case of KS during treatment with abatacept, a biologic agent targeting T‐cell costimulation. The patient was a 64‐year‐old female with rheumatoid arthritis who developed multiple firm, purple‐reddish nodules on the dorsal aspect of the right hand. Histological examination confirmed KS . What is new and conclusion Although a direct causal relationship between KS development and abatacept treatment cannot be proved, we hypothesize a role for costimulation blockade.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research